Here's Why You Should Add OPKO Health Stock to Your Portfolio

Key Takeaways OPKO Health's RAYALDEE remains its leading U.S. renal therapy, driving recent revenue growth.Partnerships with Entera Bio and asset sales to Labcorp aim to streamline operations.ModeX pipeline advances with EBV vaccine and antibody programs progressing in trials.OPKO Health, Inc. (OPK) is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competit ...